Schrodinger, Inc sold by Gates Foundation: $127m-Nov 24
On November 22, 2020, Schrödinger, Inc. (the "Company") entered into an exclusive, worldwide collaboration and license agreement (the "Agreement") with Bristol-Myers Squibb Company ("Bristol Myers Squibb"), pursuant to which the Company and Bristol Myers Squibb agreed to collaborate in the discovery, research and pre-clinical development of small molecule compounds (other than protein-degrader compounds) for biological targets in the oncology, neurology and immunology therapeutic areas.
Schrodinger, Inc. provides computational software solutions for drug discovery to the biopharmaceutical industry. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Companyâ€™s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. Its platform integrates solutions for predictive modeling, data analytics and collaboration. Its wholly-owned programs include SDGR1, SDGR2, SDGR3, SDGR4 and SDGR5. SDGR1 and SDGR2 drug discovery programs are focused on targets that mediate deoxyribonucleic acid (DNA) repair, cell cycle regulation, replication stress responses, and apoptosis, or programmed cell death. SDGR3, SDGR4 and SDGR5 drug discovery programs are focused on genetically-defined cancers. Number of employees : 394 people.
this the day before the sale from Bank of
Schrodinger Inc Registered Shs Buy